Health Economics›B-cell acute lymphoblastic leukemia›Early intensification therapy

Early intensification therapy

B-cell acute lymphoblastic leukemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CALGB 8811 early intensification Variant #01 Partial	—	R 2 530	28d	—	—	~2	~R 5 060 indirect	—
L-Asparaginase and Methotrexate Variant #01 Partial	—	R 609	—	—	—	~3	~R 1 826 indirect	—

2 of 2 regimens shown